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Abstract
Background: Array CGH has recently been introduced into our laboratory in place of karyotype analysis for
patients with suspected genomic imbalance. Results require confirmation to check sample identity, and analysis of
parental samples to determine inheritance and thus assess the clinical significance of the abnormality. Here we
describe an MLPA-based strategy for the follow-up of abnormal aCGH results.
Results: In the first 17 months of our MLPA-based aCGH follow-up service, 317 different custom MLPA probes for
novel aCGH-detected abnormalities were developed for inheritance studies in 164 families. In addition, 110 samples
were tested for confirmation of aCGH-detected abnormalities in common syndromic or subtelomeric regions using
commercial MLPA kits. Overall, a total of 1215 samples have been tested by MLPA. A total of 72 de novo
abnormalities were confirmed.
Conclusions: Confirmation of aCGH-detected abnormalities and inheritance of these abnormalities are essential for
accurate diagnosis and interpretation of aCGH results. The development of a new service utilising custom made
MLPA probes and commercial MLPA kits for follow-up studies of array CGH results has been found to be efficient
and flexible in our laboratory.
Background
Array Comparative Genomic Hybridisation (aCGH)
using either Bacterial Artificial Chromosome (BAC) or
oligonucleotide platforms is currently the method of
choice for genome-wide screening for chromosome
imbalance [1-6]. This technique is now widely used in
cytogenetic laboratories as a f o l l o w - u pt e s tf o rp a t i e n t s
with phenotype suggestive of chromosome imbalance,
but with normal karyotypes. An international consensus
statement has recently recommended array CGH as a
first-line test in place of traditional karyotype analysis
[7]; implementation of this recommendation requires
that any aCGH diagnostic service should be robust,
cost-effective and medium-throughput.
An essential component of such a service is a strategy
for confirming abnormal findings, and for establishing
the carrier status of the parents. Various strategies for
confirmation of abnormal aCGH findings have been
described, including repeat aCGH testing [8], Fluores-
cence In Situ Hybridization (FISH), microsatellite
analysis [9,10], real-time PCR [11,12] and Multiplex Liga-
tion-dependent Probe Amplification (MLPA) for specific
genes [8]. Some centres confirm abnormal findings only
for small imbalances, due to the confidence associated
with abnormal “calls” on multiple adjacent probes (perso-
nal communication), whereas others confirm all abnor-
mal findings [1,2].
Inheritance information is essential for accurate inter-
pretation of aCGH findings, and the above strategies
can also be applied for testing parental DNA [12-14].
In our laboratory, we have recently introduced oligonu-
cleotide aCGH in place of karyotype analysis [15]. In this
paper we describe an MLPA-based approach for inheri-
tance studies, and for confirmation of aCGH abnormalities
within common syndromic regions (e.g. chromosome
22q11 microdeletion region) and subtelomeric regions.
Our strategy utilises both custom-designed MLPA probes
and commercially available MLPA kits used in our existing
diagnostic service for products of conception [16] This
approach results in considerable time and efficiency sav-
ings for our aCGH service.
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Array Comparative Genomic Hybridisation
Array CGH analysis was carried out as described pre-
viously [15]. Briefly, DNA was labelled using CGH Label-
ling Kit for Oligo Arrays (Enzo Life Sciences, USA), then
applied to 44 k oligonucleotide arrays (Agilent, USA).
Image quantification, array quality control and aberration
detection were performed using Feature Extraction and
DNA Analytics software packages (Agilent, USA) accord-
ing to the manufacturer’s instructions.
DNA preparation
All DNA samples for MLPA testing were prepared and
quality tested as described previously [17,18]. DNA was
quantified by spectrophotometry (Nanodrop, USA) and
checked for degradation on an agarose gel. Degraded
DNA was not used; new samples were requested for
these cases.
MLPA custom probe design and synthesis
Custom MLPA probes were designed online using the
publicly available Human MLPA Probe Design algo-
rithm (H-MAPD; http://genomics01.arcan.stonybrook.
edu/mlpa/cgi-bin/mlpa.cgi) [19]. Probes of various sizes
were designed by specifying the required length of liga-
tion product, with no stuffer sequence. The suggested
probe sequences were subjected to BLAT searches
http://genome.ucsc.edu/ to verify genomic position and
sequence homology. Right hybridizing sequences (RHS)
were ordered as 5’ phosphorylated “Ultramer” oligonu-
cleotides and left hybridizing sequences (LHS) were
ordered as standard desalted oligonucleotides (Inte-
grated DNA Technologies, Belgium).
Custom MLPA assay selection
MRC-Holland manufacture two MLPA kits, P200 and
P300, designed for use with custom MLPA probes. These
kits combine reference probes for data normalization and
quantity/quality control fragments with space for the
addition of multiple custom probes. Both kits were
trialled and a final decision made to routinely use the
P200 kit as it allowed shorter and therefore cheaper cus-
tom probes to be used than the P300 kit. The P300 kit is
preferred by users who observe significant effects of sig-
nal sloping on their data and counters this problem by
distributing reference probes over the whole size range of
the probemix. This signal sloping effect was not observed
to a significant degree with our data.
Up to three custom MLPA probes, differing in size by at
least ten base pairs, were run concurrently in a single
probe mix (see Figure 1). This reduced costs by reducing
the number of normal control reactions and the associated
consumables needed. The potential for making efficiency
and consumable savings by increasing the number of
probes per mix must be weighted against the cost of
probes of increasing size. In our laboratory the most effi-
cient scenario involves the use of three separate four
probe mixes, with three family members tested per probe.
This allows 12 families to be tested per 96 well plate.
Multiplex Ligation-dependent Probe Amplification
MLPA reactions using MRC-Holland SALSA® P245, P36E
and P69 kits were carried out according to the manufac-
turer’s instructions and as described previously [17].
Custom MLPA probes were prepared and diluted and
reactions performed according to the synthetic MLPA
protocol provided on the MRC-Holland website http://
mlpa.com.
No optimisation of custom probe concentration was
required. Peak heights were found to be generally com-
parable to those of the P200 reference probes when
probes were added at the concentrations recommended
by MRC-Holland.
DNA samples tested with custom probes were tested
in duplicate; two normal control samples, each tested in
triplicate, and a negative control were included for every
custom probe mix. The proband was always tested
alongside parental samples to confirm assay sensitivity.
MLPA data analysis
A3μl aliquot of PCR product was mixed with 0.3 μlG e n -
escan 500 LIZ size standard (Applied Biosystems, UK) and
15 μl HiDi formamide (Applied Biosystems, UK) before
being size-separated by capillary electrophoresis on a 3730
genetic analyser (Applied Biosystems, UK) according to
the manufacturer’s instructions.
MLPA peak height data was analysed using GeneMarker
v1.8 software (SoftGenetics, USA). A maximum raw data
peak height of 15,000 relative fluorescent units (rfu) was
established after observing a loss of peak height relative
dosage with increasing concentrations of DNA. Peak
heights which were too low also produced unreliable
dosage ratios; a lower peak height limit was set at 250 rfu.
Results with peak heights outside of these limits were
failed and the sample re-processed.
P36, P69 and P245 MLPA kits
Data from the P36E and P69 subtelomere kits and the
P245 microdeletion/microduplication kit were inter-
preted according to analysis parameters described pre-
viously [18].
Custom MLPA
Peak height data from MRC-Holland P200 kits with
added custom probes were analysed according to recom-
mendations on data normalization provided on the
MRC-Holland website. Panels were designed to detect
one or more custom probes per kit.
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selected so that sample data was only compared to user-
specified control data rather than to the whole run. Cus-
tom probe peaks were not included in the normalization
The MLPA Analysis function in GeneMarker was used
for determining copy number of custom probes with
MLPA peak height ratios defined as deletion < 0.71 ≤ nor-
mal ≤ 1.23 ≤ duplication (as described by [17]). Figure 1
shows an example trace.
For a result to be called, at least one out of three
replicates for each control sample must pass (i.e. peak
height within limits and no outlying probe peaks), and
both duplicate patient results must be concordant. Sam-
ples with reference probe peak ratios which fell outside
of the normal range were failed (see Figure 1e), as were
samples with high QC fragment peaks.
This analysis approach is sim i l a rt ot h a tu s e df o ro u r
diagnostic service for the molecular analysis of miscar-
riage products [16].
Genotyping
Genotyping for relationship testing (in families where
the abnormality in the proband had apparently arisen de
novo) was carried out using multiplex quantitative fluor-
escence PCR (QF-PCR) assays containing multiple poly-
morphic STR markers which are routinely used in our
department for aneuploidy diagnosis [20,21].
Results
In the period from January 2009 to May 2010, 3306 array
CGH tests were carried out in our laboratory. The follow-
ing sections refer to MLPA results obtained within this
time period.
Confirmation of array CGH results and inheritance studies
using custom MLPA probes
When parental blood samples were received for follow-
u ps t u d i e so fa C G Hf i n d i n g sn o tc o v e r e db yp r o b e si n
MRC-Holland P36, P69 or P245 kits, a custom MLPA
Figure 1 MLPA results of three custom probes in the MRC-Holland P200 kit. GeneMarker electrophoretograms are shown on the left, normalized
MLPA data on the right. The 184 bp peak represents the D-fragment which is used to highlight incomplete denaturation and is not shown in the
analysed data on the right, the 241 bp fragment is a Y chromosome specific fragment for the identification of male samples. a) normal female control
sample b) female sample with decreased copy number for the 120 bp probe c) male sample with increased copy number for the 130 bp probe d)
female sample with decreased copy number for the 140 bp probe e) poor quality male sample with several outlying probes.
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was designed. Potentially relevant genes were targe-
ted and common copy number variants (CNV) were
avoided.
During this period, 317 unique custom MLPA probes
were designed for 164 families in order to determine
inheritance of both duplication and deletion results, and
were tested on a total of 1105 individuals. Figure 2
depicts the spread of custom probes across the genome.
The majority of custom probes were used for only sin-
gle families; however, certain regions have started to
emerge as exhibiting recurrent deletions and/or duplica-
tions. This may be due to previously unidentified recur-
rent syndromic regions, or may represent benign
population polymorphisms. To date, the probe with the
greatest usage is located at Xp22.31. This has been used
for 11 families. Duplication of this region has been
found in patients with a range of different phenotypes,
and also in normal parents, both male and female, and
has therefore been suggested as a benign variant [22].
The reciprocal deletion gives rise to steroid sulphatase
deficiency in male carriers (OMIM 306480).
In addition, a custom probe has been designed for the
autism susceptibility locus on chromosome 16p11.2
[23-25]. Copy number changes within this region are fre-
quently detected by aCGH and are very likely to arise fol-
lowing unequal meiotic crossing over between flanking
low-copy repeats. Custom MLPA can therefore be used
to confirm the abnormality, thus eliminating the need for
repeat aCGH testing in such cases. Within our data set,
this custom MLPA probe has been used to confirm copy
number changes and for inheritance studies in five
families.
Twenty seven custom MLPA probes (8.5%) failed, due
to either amplification failure or inconsistent results. In
all cases, replacement probes were designed.
Confirmation of subtelomeric abnormalities and common
microdeletion/microduplications detected by aCGH
During this period, 49 samples from 28 families were
tested using subtelomere kits (P36E and P69) for follow-
up of aCGH results. Three de novo terminal abnormalities
were confirmed out of a total of nine where inheritance
studies have been completed; a chromosome 9p deletion,
Figure 2 Karyotype illustrating the spread of custom probes across the genome. Black bars indicate that a probe has been tested on one
family, red bars indicate that a probe has been tested on more than one family.
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the P36E kit which contains a probe for the proximal
region of the long arm of chromosome 13) and an unba-
lanced translocation between the telomeric regions of the
short arms of chromosomes 5 and 8.
In the same period, 61 samples from 32 families were
tested using microdeletion/microduplication kits (P245)
for follow-up of aCGH results. Eleven de novo results
were confirmed out of a total of twelve where inheri-
tance studies had been completed; six deletions of the
chromosome 22q11 microdeletion/microduplication
region, three abnormalities in the Prader Willi/Angel-
man syndrome region, one duplication of the Smith-
Magenis region, one partial deletion of the Miller-Dieker
region, one deletion of the NF1 region, one deletion of
the Alagille region and one duplication of the Williams
Beuren region. One case of an inherited chromosome
22q11 duplication was also confirmed.
Discrepant results
We observed no discrepancies between array CGH
results and MLPA results. Apparent discrepancies may
arise due to SNPs close to the ligation site of the two
probe hybridising sequences, causing amplification fail-
ure, and therefore mimicking a deleted result. This is
mitigated by using the H-MAPD software which checks
potential probe sequences against the latest SNP
database.
Results turnaround times
Confirmation and inheritance results were generally
available within two weeks of sample receipt. Probes
were usually synthesized and dispatched by IDT within
five working days of ordering. Tests using existing
stocks of probes could be turned around in less than a
week in urgent cases. The rate of repeat testing due
poor DNA quality or discordant probe results was 14%.
Discussion
Array CGH testing for genomic imbalance has been intro-
duced as a first-line test in place of G-banded chromo-
some analysis in a number of centres, and is offered as an
additional test by most cytogenetics laboratories. As with
any test protocol that involves the simultaneous handling
of multiple DNA samples, it is important that any abnor-
mal results are confirmed in order to establish patient
identity before reporting. However, repeat array CGH test-
ing of all abnormal findings, and array testing of parental
samples for inheritance studies adds significantly to the
cost of the service and may also result in incidental find-
ings potentially requiring further investigation.
MLPA is now an established technique for the investi-
gation of copy number [26]. MRC-Holland http://www.
mrc-holland.com manufactures numerous commercial
MLPA kits for the detection of copy number changes
in different genomic locations. We currently use three
of these kits (P36E, P69 and P245) in our recently
described diagnostic service for the molecular analysis
of miscarriage products [16]. Prior to the introduction
of aCGH into our laboratory we also used these kits for
the diagnosis of subtelomeric imbalance (P36E and P69)
and common microdeletion/microduplication syn-
dromes (P245) in patients with idiopathic developmental
delay and/or dysmorphism [17]. We therefore have in
operation in our laboratory an efficient and medium
throughput diagnostic MLPA-based service and have
refined our sample preparation and data analysis techni-
ques to improve accuracy and turnaround times. We
were able to exploit this existing service in order to
develop an efficient follow-up strategy for aCGH testing.
However, the approach we describe should also be feasi-
ble in centres with an appropriate genetic analyser with-
out previous experience of this technique, as extensive
technical support is available from MRC-Holland, and
DNA preparation, probe design, reaction set up and
data analysis protocols are readily available. In our
experience, optimisation is not required for the majority
of custom MLPA probes. Furthermore, the use of cus-
tom MLPA probes represents a simple method for
establishing copy number beyond the usage described in
this paper.
This approach results in significant time and cost sav-
ings by avoiding the need for aCGH testing for confirma-
tion of common abnormalities or of parental samples.
Other follow-up approaches that have been described
include FISH, which has the advantage of giving position
information, and excluding balanced rearrangements in
parents, in cases of apparent de novo findings [13]. How-
ever, this approach requires cell culture in order to exam-
ine chromosome spreads, whereas MLPA is performed
on the same DNA sample as is used for the original
aCGH analysis; in addition some regions of imbalance
detected by aCGH are too small to be followed up by
routinely-available FISH probes. Nevertheless, where
FISH probes are available, we offer FISH testing to par-
ents of children with de novo abnormalities, in order to
refine their reproductive risk; no families have yet
requested this testing. We have compared real-time PCR
as a follow-up strategy and have found it to be more
costly and time-consuming than MLPA (results not
shown).
Follow-up of aCGH results using STR markers and
QF-PCR is limited by a lack of polymorphic markers,
time taken for optimization and the inability to confirm
deletions in the absence of parental genotypes. How-
ever, we are able to confirm common trisomies using
the multiplex QF-PCR kits designed for our prenatal
service [20,27].
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Follow-up of abnormal aCGH results is good practice to
confirm patient identity, and inheritance studies are
necessary for accurate interpretation of these abnormal
findings. The results presented here demonstrate that
MLPA is a fast, robust and accurate technique for con-
firmation and follow-up of both duplication and deletion
aCGH results. However, exclusion of balanced parental
rearrangements by FISH is recommended for apparently
de novo abnormalities.
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